for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Titan Pharmaceuticals, Inc.

TTNP.OQ

Latest Trade

0.17USD

Change

0.01(+3.09%)

Volume

789,236

Today's Range

0.16

 - 

0.17

52 Week Range

0.14

 - 

0.59

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.16
Open
0.17
Volume
789,236
3M AVG Volume
105.24
Today's High
0.17
Today's Low
0.16
52 Week High
0.59
52 Week Low
0.14
Shares Out (MIL)
97.22
Market Cap (MIL)
16.03
Forward P/E
-1.22
Dividend (Yield %)
--

Latest Developments

More

Titan's Probuphine Commercialization Partner, Molteni, Enters Exclusive European Distribution Agreement With Accord

Titan Pharmaceuticals Reports Q2 Loss Per Share $0.05

Titan Pharmaceuticals - Cash Resources Are Only Sufficient To Fund Operations Through Q3 Of This Year

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Titan Pharmaceuticals, Inc.

Titan Pharmaceuticals, Inc. (Titan) is a specialty pharmaceutical company. The Company is engaged in developing therapeutics for the treatment of medical disorders. The Company's segment is engaged in the development of pharmaceutical products. The Company's product development programs utilize its long-term drug delivery platform, ProNeura. The Company's drug candidate, Probuphine, is being developed for the long-term maintenance treatment of opioid dependence. Titan's ProNeura continuous drug delivery system consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The Company focuses on developing two product development programs, the first one with a ropinirole implant for the treatment of Parkinson's disease (PD) and the second one with a Triiodothyronine (T3) implant for the treatment of hypothyroidism.

Industry

Biotechnology & Drugs

Contact Info

400 Oyster Point Blvd Ste 505

SOUTH SAN FRANCISCO, CA

94080-1958

United States

+1.650.2444990

https://www.titanpharm.com/

Executive Leadership

Marc Rubin

Executive Chairman of the Board

Sunil Ramraje Bhonsle

President, Chief Executive Officer, Director

Katherine Beebe DeVarney

Executive Vice President, Chief Scientific Officer, Director

Joseph A. Akers

Independent Director

M. David MacFarlane

Independent Director

Key Stats

3.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

-4.020

2018

-0.780

2019

-0.720

2020(E)

-0.160
Price To Earnings (TTM)
--
Price To Sales (TTM)
3.32
Price To Book (MRQ)
10.28
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
318.53
LT Debt To Equity (MRQ)
214.42
Return on Investment (TTM)
-463.38
Return on Equity (TTM)
-205.40

Latest News

Latest News

BRIEF-Titan Pharmaceuticals Urges Stockholders To Vote "For" Proposal To Amend Its Certificate Of Incorporation

* TITAN PHARMACEUTICALS URGES STOCKHOLDERS TO VOTE "FOR" PROPOSAL TO AMEND ITS CERTIFICATE OF INCORPORATION Source text for Eikon: Further company coverage:

BRIEF-Titan Pharmaceuticals - Cash Resources Are Only Sufficient To Fund Operations Through Q3 Of This Year

* TITAN PHARMACEUTICALS - CO'S CURRENT CASH RESOURCES ARE ONLY SUFFICIENT TO FUND OPERATIONS THROUGH Q3 OF THIS YEAR

BRIEF-Titan Pharmaceuticals And Indegene Enter Into Probuphine Co-Promotion Partnership

* TITAN PHARMACEUTICALS AND INDEGENE ENTER INTO PROBUPHINE® CO-PROMOTION PARTNERSHIP Source text for Eikon: Further company coverage:

BRIEF-Titan Pharmaceuticals Q1 Loss Per Share $0.07

* TITAN PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS

BRIEF-Titan Pharmaceuticals Reports Q4 Loss Per Share $0.08

* TITAN PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS

BRIEF-Titan Pharmaceuticals Says Nasdaq Provided Extension To Regain Compliance

* TITAN PHARMACEUTICALS - RECEIVED LETTER FROM NASDAQ PROVIDING CO WITH 180-DAY EXTENSION TO REGAIN COMPLIANCE WITH LISTING REQUIREMENT Source text: (http://www.sec.gov/archives/edgar/data/910267/000110465920035935/0001104659-20-035935-index.htm ) Further company coverage:

BRIEF-Titan Pharmaceuticals Q1 Loss Per Share $0.12

* TITAN PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Titan Pharmaceuticals: Names Federico Seghi Recli To Board

* ACCOMPLISHED GLOBAL PHARMACEUTICAL EXECUTIVE, FEDERICO SEGHI RECLI, APPOINTED TO TITAN'S BOARD Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Titan Pharmaceuticals Q4 Loss Per Share $0.17

* TITAN PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Titan Pharmaceuticals Executes Agreement For Acquisition By Molteni Of Probuphine In Europe And Other Territories

* TITAN EXECUTES AGREEMENT FOR ACQUISITION BY MOLTENI OF PROBUPHINE® IN EUROPE AND OTHER SELECT TERRITORIES

BRIEF-Titan Announces Amendment To Horizon Loan Agreement

* TITAN PHARMACEUTICALS INC - ENTRY INTO AN AMENDMENT TO JULY 2017 LOAN AGREEMENT WITH HORIZON TECHNOLOGY FINANCE CORPORATION

BRIEF-Titan Pharmaceuticals Says Co​ Entered Into A Binding Term Sheet With L. Molteni & C. Dei F.Lli Alitti Societ*I Esercizio

* TITAN PHARMACEUTICALS INC - ON NOV 27, CO ENTERED INTO A BINDING TERM SHEET WITH L. MOLTENI & C. DEI F.LLI ALITTI SOCIET*I ESERCIZIO - SEC FILING

BRIEF-Titan Pharmaceuticals Partners With Molteni To Market Probuphine In Europe

* TITAN PHARMACEUTICALS PARTNERS WITH MOLTENI TO MARKET PROBUPHINE® IN EUROPE

CORRECTED-BRIEF-European Medicines Agency Accepts Titan's Marketing Application For Probuphine

* EUROPEAN MEDICINES AGENCY ACCEPTS TITAN PHARMACEUTICALS' MARKETING AUTHORIZATION APPLICATION FOR PROBUPHINE®

BRIEF-Titan Pharmaceuticals reports Q3 loss per share of $0.20

* Titan pharmaceuticals reports third quarter 2017 financial results

BRIEF-Titan Pharmaceuticals files for offering of up to 280,612 shares by selling stockholder

* Titan Pharmaceuticals Inc files for offering of up to 280,612 shares of co's common stock by the selling stockholder - SEC filing Source text:[http://bit.ly/2izOUEZ] Further company coverage:

BRIEF-Titan Pharmaceuticals and Opiant Pharmaceuticals collaborate to explore a new approach to opioid use disorder treatment

* Titan Pharmaceuticals and Opiant Pharmaceuticals collaborate to explore a new approach to opioid use disorder treatment

BRIEF-Opiant Pharma, Titan Pharmac to explore new treatments for opioid abuse

* Opiant Pharmaceuticals and Titan Pharmaceuticals collaborate to explore a new approach to opioid use disorder treatment

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up